Siddha Research

Tuesday, January 3, 2012

Monograph on Athimathuram

Glycyrrhiza glabra Monograph

Page 230 Alternative Medicine Review u Volume 10, Number 3 u 2005

Glycyrrhiza

glabra

Introduction

Glycyrrhiza glabra, also known as licorice and sweetwood, is native to the Mediterranean and certain areas

of Asia. Historically, the dried rhizome and root of this plant were employed medicinally by the Egyptian, Chinese,

Greek, Indian, and Roman civilizations as an expectorant and carminative. In modern medicine, licorice extracts

are often used as a flavoring agent to mask bitter taste in preparations, and as an expectorant in cough and cold

preparations. Licorice extracts have been used for more than 60 years in Japan to treat chronic hepatitis, and also

have therapeutic benefit against other viruses, including human immunodeficiency virus (HIV), cytomegalovirus

(CMV), and Herpes simplex. Deglycyrrhizinated licorice (DGL) preparations are useful in treating various types

of ulcers, while topical licorice preparations have been used to sooth and heal skin eruptions, such as psoriasis and

herpetic lesions.

Description

The licorice shrub is a member of the pea family and grows in subtropical climates in rich soil to a height

of four or five feet. It has oval leaflets, white to purplish flower clusters, and flat pods. Below ground, the licorice

plant has an extensive root system with a main taproot and numerous runners. The main taproot, which is harvested

for medicinal use, is soft, fibrous, and has a bright yellow interior.1 Glycyrrhiza is derived from the ancient Greek

term glykos, meaning sweet, and rhiza, meaning root.

Active Constituents

A number of components have been isolated from licorice, including a water-soluble, biologically active

complex that accounts for 40-50 percent of total dry material weight. This complex is composed of triterpene saponins,

flavonoids, polysaccharides, pectins, simple sugars, amino acids, mineral salts, and various other substances.2

Glycyrrhizin, a triterpenoid compound, accounts for the sweet taste of licorice root. This compound represents a

mixture of potassium-calcium-magnesium salts of glycyrrhizic acid that varies within a 2-25 percent range. Among

the natural saponins, glycyrrhizic acid is a molecule composed of a hydrophilic part, two molecules of glucuronic

acid, and a hydrophobic fragment, glycyrrhetic acid.2 The yellow color of licorice is due to the flavonoid content of

the plant, which includes liquiritin, isoliquiritin (a chalcone), and other compounds.3 The isoflavones glabridin and

hispaglabridins A and B have significant antioxidant activity,4 and both glabridin and glabrene possess estrogen-like

activity.5

COOH

HO O

HO COOH

COOH

Glycyrrhizin

Monograph Glycyrrhiza glabra

Alternative Medicine Review u Volume 10, Number 3 u 2005 Page 231

Pharmacokinetics

After oral administration of licorice in humans,

the main constituent, glycyrrhizic acid, is hydrolyzed

to glycyrrhetic acid by intestinal bacteria

possessing a specialized ß-glucuronidase.6,7 Glycyrrhetic

acid is 200-1,000 times more potent an inhibitor

of 11-ß-hydroxysteroid dehydrogenase (involved

in corticosteroid metabolism) than glycyrrhizic acid;

therefore, its pharmacokinetics after oral intake are

more relevant. After oral dosing, glycyrrhetic acid

is rapidly absorbed and transported via carrier molecules

to the liver. In the liver it is metabolized to

glucuronide and sulfate conjugates, which are subsequently

rehydrolyzed to glycyrrhetic acid. Glycyrrhetic

acid is then reabsorbed, resulting in a significant

delay in terminal clearance from plasma.8 After

oral administration of 100 mg glycyrrhizin in healthy

volunteers, no glycyrrhizin was found in the plasma

but glycyrrhetic acid was found at < 200 ng/mL. In

the 24-hour period after oral administration, glycyrrhizin

was found in the urine, suggesting it is partly

absorbed as an intact molecule.3

Mechanisms of Action

The beneficial effects of licorice can be attributed

to a number of mechanisms. Glycyrrhizin

and glycyrrhizic acid have been shown to inhibit

growth and cytopathology of numerous RNA and

DNA viruses, including hepatitis A9 and C,10,11 herpes

zoster,12 HIV,13,14 Herpes simplex,15,16 and CMV.17

Glycyrrhizin and its metabolites inhibit hepatic

metabolism of aldosterone and suppress 5-ßreductase,

properties responsible for the well-documented

pseudoaldosterone syndrome. The similarity

in structure of glycyrrhetic acid to the structure of

hormones secreted by the adrenal cortex accounts for

the mineralocorticoid and glucocorticoid activity of

glycyrrhizic acid.18

Licorice constituents also exhibit steroidlike

anti-inflammatory activity, similar to the action

of hydrocortisone. This is due, in part, to inhibition

of phospholipase A2 activity, an enzyme critical to

numerous inflammatory processes.19 In vitro research

has also demonstrated glycyrrhizic acid inhibits cyclooxygenase

activity and prostaglandin formation

(specifically prostaglandin E2), as well as indirectly

inhibiting platelet aggregation, all factors in the

inflammatory

process.

19,20

Certain licorice constituents possess significant

antioxidant and hepatoprotective properties.

Glycyrrhizin and glabridin inhibit the generation of

reactive oxygen species (ROS) by neutrophils at the

site of inflammation.21,22 In vitro studies have demonstrated

licorice isoflavones, hispaglabridin A and B,

inhibit Fe3+-induced mitochondrial lipid peroxidation

in rat liver cells.23 Other research indicates glycyrrhizin

lowers lipid peroxide values in animal models of

liver injury caused by ischemia reperfusion.24 Licorice

constituents also exhibit hepatoprotective activity by

lowering serum liver enzyme levels and improving

tissue pathology in hepatitis patients.25

Glycyrrhizin and other licorice components

appear to possess anticarcinogenic properties as well.

Although the exact mechanisms are still under investigation,

research has demonstrated they inhibit abnormal

cell proliferation, as well as tumor formation

and growth in breast,26 liver,27 and skin28,29 cancer.

Deglycyrrhizinated licorice formulations

used in the treatment of ulcers do not suppress gastric

acid release like other anti-ulcer medications. Rather,

they promote healing by increasing mucous production

and blood supply to the damaged stomach mucosa,

thereby enhancing mucosal healing.30,31

Glycyrrhiza glabra Monograph

Page 232 Alternative Medicine Review u Volume 10, Number 3 u 2005

Clinical Indications

Chronic Hepatitis

In Japan, glycyrrhizin has been used for more

than 60 years as a treatment for chronic hepatitis C.

Stronger Neo-Minophagen C (SNMC), a glycyrrhizin

preparation, has been extensively used with considerable

success. In two clinical trials, SNMC has

been shown to significantly lower aspartate transaminase

(AST), alanine transaminase (ALT), and gamma-

glutamyltransferase (GGT) concentrations, while

simultaneously ameliorating histologic evidence of

necrosis and inflammatory lesions in the liver.25,32 In

recent years, several studies have been performed

supporting this action.10,11 Presently, interferon (IFN)

therapy is a predominant treatment for chronic hepatitis.

Because its efficacy is limited, an alternative

treatment is desirable. SNMC has profound effects on

the suppression of liver inflammation and is effective

in improving chronic hepatitis and liver cirrhosis. It

also appears to have considerably fewer side effects

than IFN.33

In a double-blind, randomized, placebo-controlled

trial investigating IV infusions of SNMC,

short-term efficacy of licorice was confirmed with

regard to ALT levels. The study showed the need for

daily IV administration of SNMC, which may be impractical

for patients. The study also demonstrated

that after cessation of therapy the ALT-decreasing effect

of licorice disappeared, suggesting the need for

long-term administration.25

Oral Lichen Planus

Patients with chronic hepatitis C often experience

oral lichen planus, an inflammatory disease characterized

by lymphocytic hyperkeratosis of the oral

mucosa. It is rarely cured and effective treatments are

limited. In an open clinical trial, 17 hepatitis C-positive

patients with oral lichen planus were given either

routine dental care or 40 mL IV glycyrrhizin daily for

one month. Among nine patients taking glycyrrhizin,

six (66.7%) noted improved clinical symptoms, such

as decreased redness, fewer white papules, and less

erosion of the mucosa. In the non-glycyrrhizin group

of eight patients, only one (14.3%) reported any improvement.

Other Viral Illnesses

It has been reported that licorice inhibits

growth and cytopathology of many unrelated DNA

and RNA viruses, while not affecting cell activity or

cellular replication.15

Hepatitis A virus (HAV) causes acute hepatitis,

a major public health concern in numerous countries.

In vitro research with glycyrrhizin and a human

hepatoma cell line has demonstrated glycyrrhizin

completely suppresses the expression of the HAV antigen.

In comparison to ribavirin (an antiviral agent

used to treat hepatitis), glycyrrhizin proved to be 10

times more potent at reducing infectivity of HAV, as

measured by reduction in viral titres. Glycyrrhizin

also exhibited a five-fold greater cell selectivity than

ribavirin in that it was less cytotoxic to the hepatoma

cells. These results indicate glycyrrhizin may be a

potential therapeutic adjunct in fighting HAV infections.

Studies show licorice and its constituents,

specifically glycyrrhizin, have antiviral activity

against Herpes simplex and are capable of irreversibly

inactivating the virus.16,35,36 Glycyrrhizin has also

been shown to inhibit viral replication and infectivity

of HIV,14,36 herpes zoster,37 Varicella zoster,12 and

CMV.17,38,39

A case report demonstrated a two-percent topical

glycyrrhizic acid cream (carbenoxolone sodium)

applied six times daily in 12 patients with acute oral

herpetic (Herpes simplex) infections resolved pain

and dysphagia within 24-48 hours of beginning use.

Moreover, the accompanying ulceration and lymphadenopathy

gradually healed within 24-72 hours.16

A clinical study of three HIV patients with

hemophilia investigated the effect of glycyrrhizin on

HIV replication. Glycyrrhizin was administered IV at

400-1600 mg on six separate occasions over a onemonth

period. The HIV p24 antigen was detected in

all patients at the beginning of treatment courses. At

the end of one month, p24 antigen levels had either

decreased significantly or become negative. Tapering

of the glycyrrhizin dose resulted in an immediate elevation

in p24 antigen levels, suggesting the higher

doses of glycyrrhizin were responsible for decreased

antigen levels, probably via suppressed viral replication.

Monograph Glycyrrhiza glabra

Alternative Medicine Review u Volume 10, Number 3 u 2005 Page 233

In a clinical trial of 31 patients with severely

painful herpes zoster lesions, 12 patients were given

20 mg IV glycyrrhizin on six separate occasions. The

remaining 19 patients received either zoster immune

gamma-globulin, recombinant interferon-ß, or acyclovir.

Glycyrrhizin ranked next to acyclovir for pain

resolution at the end of one month.37

CMV is the most common cause of congenital

and perinatal viral infections throughout the world.

It manifests with profound liver dysfunction and poor

weight gain. In a series of studies, both oral and IV

preparations of licorice (SNMC) were administered

to infants with CMV. Liver dysfunction and weight

gain improved in nearly all cases compared to groups

without treatment.17,38,39

Hepatocellular Carcinoma

In a retrospective study, long-term licorice

administration for hepatitis C infection was effective

in preventing hepatocellular carcinoma (HCC). Four

hundred fifty-three patients diagnosed with hepatitis

C were divided into three groups and given either

licorice, in the form of SNMC at a dose of 100 mL

daily for two months, or other natural treatments,

such as vitamin K. The remaining group of patients

was treated with a wider number of agents, including

SNMC, corticosteroids, and immunosuppressive

agents; as a result of the mixed medication regimen,

this group was excluded from the study. After 10

years, analysis of the results showed 30/84 patients

(35.7%) employing SNMC had normalized AST levels,

compared with seven patients (6.4%) not treated

with IV SNMC. Moreover, the 10- and 15-year appearance

rate of HCC was 7 and 12 percent in the

treated group compared to 12 and 25 percent in the

untreated group, respectively.40 A summary of the literature

on HCC and the use of SNMC has confirmed

that IV glycyrrhizin not only decreases ALT levels

but also improves liver histology and decreases incidence

of hepatic cirrhosis.41

Aphthous Ulcers

In a double-blind, placebo-controlled trial,

24 patients with recurrent aphthous ulcers were randomly

allocated to consume 2 g glycyrrhizin (carbenoxolone

sodium) in 30 mL of warm water or a

placebo three times daily following meals for four

weeks. In contrast to the placebo group, the use of the

oral licorice mouthwash significantly reduced the average

number of ulcers per day, pain scores, and the

development of new ulcers.42 In a study of 20 patients

instructed to use a DGL mouthwash four times daily,

15 experienced 50-75 percent clinical improvement

after only one day, with complete healing of canker

sores after three days.43

Peptic Ulcer Disease

Licorice has been used as a demulcent and

emollient for 2,000 years to promote the healing of

ulcers by acting on the mucosal layer. Glycyrrhizin

(as carbenoxolone sodium) speeds healing of gastric

ulcers and protects against aspirin-induced damage to

the gastric mucosa. In a double-blind, placebo-controlled

study, 70 patients with endoscopically-confirmed

gastric or duodenal ulcers were given carbenoxolone

sodium 300 mg or placebo daily during the

first seven days, followed by 150 mg daily over the

next 3-5 weeks. The authors concluded the carbenoxolone

group had an increase in pH at the stomach

antrum from 1.1 to 6.0, and a reduction in basal and

histamine-induced gastric acid secretion at pH 3 and

5. Overall, 70 percent of ulcers in the glycyrrhizin

group healed within 3-5 weeks of beginning therapy,

compared to 36 percent employing placebo.44

Unfortunately, the side effects of licorice

limit its potential to be used on a long-term basis for

treatment of peptic ulcer disease. A processed form

of licorice, DGL (removal of the glycyrrhizin), was

produced to eliminate potential adverse effects, including

licorice-induced hypertension.45 In a double-

blind trial, 100 patients were randomly chosen

to chew Caved S (DGL plus antacid), 760 mg three

times daily, or take cimetidine (Tagamet®) 200 mg

three times daily and 400 mg at night for 12 weeks.

Endoscopy showed the healing rate between the two

regimens was comparable at six (63 percent) and 12

(91 percent) weeks. Although both therapies reduced

pain symptom scores in a comparable fashion during

the day, cimetidine was more effective during the first

two weeks at reducing nighttime pain.46 A two-year

follow-up trial comparing the two therapies in the

prevention of gastric ulcer recurrence noted the outCopyright

Glycyrrhiza glabra Monograph

Page 234 Alternative Medicine Review u Volume 10, Number 3 u 2005

comes were similar, with a reported relapse rate of 29

percent (9/31) in the Caved S group and 25 percent

(8/32) in the cimetidine group.47

Other clinical trials have demonstrated the

effectiveness of DGL for gastric ulcer.48,49 A fourweek

clinical trial by Turpie et al demonstrated a

statistically significant greater reduction in ulcer size

in patients receiving 760 mg of a DGL preparation

compared to placebo.48

Helicobacter pylori infection is prevalent in

individuals with peptic ulcer and is also a known risk

factor for gastric cancer.50,51 Consequently, an in vitro

study was performed to investigate the effects of licorice

flavonoids on the growth of H. pylori. These flavonoid

components showed promising anti-H. pylori

activity against clarithromycin- and amoxicillin-resistant

strains. As the antimicrobial property seems to

be attributed to the flavonoid constituents of licorice,

DGL preparations may provide therapeutic benefit

for H. pylori infection.52

Other studies have demonstrated DGL’s benefit

in healing duodenal ulcers. In a trial of 40 patients

receiving either 3.0 or 4.5 g DGL daily for eight

weeks, all patients showed significant improvement

after 5-7 days. Patients were assessed for relief from

epigastric pain, nausea, vomiting, x-ray of ulcer craters

to determine changes in size, and frequency of

relapse (return of ulcer pain for two days per week).

Patients receiving the higher DGL dose showed the

most improvement.53 In a large study of 874 patients

with chronic duodenal ulcers, patients received either

DGL, cimetidine, or antacids. Ninety-one percent of

all ulcers healed, regardless of treatment type. Differences

among treatment groups were not statistically

significant, but patients in the DGL group experienced

the fewest relapses.54

Other Therapeutic Considerations

In a trial of 15 normal-weight subjects (seven

males, eight females, ages 22-26), 3.5 mg of a commercial

licorice preparation daily for two months resulted

in a decrease in body fat mass. Plasma renin

activity and aldosterone were also suppressed. No

changes in body mass index were noted. These results

indicate licorice and its constituents can reduce

body fat by inhibiting 11-ß-hydroxysteroid dehydrogenase

in fat cells.55

Armanini et al investigated the effect of licorice

on serum testosterone in nine healthy women,

ages 22-26, using the same licorice preparation as

above, and found total serum testosterone decreased

from 27.8 (± 8.2) to 19.0 (± 9.4) ng/dL after one

month, and further decreased to 17.5 (± 6.4) ng/dL

after the second month of therapy. This is likely due

to inhibition of 17-hydroxysteroid dehydrogenase,

indicating

licorice may be of benefit in treating women

with hirsutism and polycystic ovary syndrome.56

Several animal and in vitro studies indicate

glycyrrhizin and its constituents possess anticarcinogenic

activity against a variety of cancers, warranting

further investigation in clinical trials.26-29

Studies also show licorice constituents to be

effective in the treatment of eczema,57 melasma,58 eosinophilic

peritonitis,59 postural hypotension,60 erosive

gastritis,61 and as anti-malarial62 and anti-Leishmanial

agents.63 More recently, animal studies indicate aqueous

extracts of G. glabra may have memory-enhancing

activity via reversal of chemically-induced amnesia,

as measured by maze and passive avoidance

testing in mice.64

Drug-Botanical Interactions

There is an increased likelihood of cardiac

arrhythmias, particularly in individuals with ischemic

heart disease, when licorice is used in conjunction

with digoxin.65

Estrogen-based oral contraceptives may enhance

the mineralocorticoid side effects of licorice in

susceptible individuals. This may be due in part to estrogens

reacting with mineralocorticoid receptors or

inhibition of 11â-hydroxysteroid dehydrogenase.66

Hypokalemia, commonly associated with

metabolic acidosis, may co-present with essential

benign hypertension in patients using diuretics and

licorice simultaneously.67

Side Effects and Toxicity

One of the most commonly reported side effects

with licorice supplementation is elevated blood

pressure. This is thought to be due to the effect of

licorice on the renin-angiotensin-aldosterone system.

It is suggested licorice saponins are capable of potentiating

aldosterone action while binding to mineralocorticoid

receptors in the kidneys. The phenomenon

Monograph Glycyrrhiza glabra

Alternative Medicine Review u Volume 10, Number 3 u 2005 Page 235

is known as “pseudoaldosteronism.” In addition to

hypertension, patients may experience hypokalemia

(potassium loss) and sodium retention, resulting

in edema. All symptoms usually disappear with

discontinuation of therapy.25 Many studies report no

side effects during the course of treatment.32,33 Generally,

the onset and severity of symptoms depend on

the dose and duration of licorice intake, as well as

individual susceptibility. Patients with delayed gastrointestinal

transit time may be more susceptible to

these side effects, due to enterohepatic cycling and

reabsorption of licorice metabolites. The amount of

licorice ingested daily by patients with mineralocorticoid

excess syndromes appears to vary over a wide

range, from as little as 1.5 g daily to as much as 250

g daily.68

Dosage

Because individual susceptibility to various

licorice preparations is vast, it is difficult to predict

a dose appropriate for all individuals. Nevertheless,

a daily oral intake of 1-10 mg of glycyrrhizin, which

corresponds to 1-5 g licorice (2% glycyrrhizin), has

been estimated to be a safe dose for most healthy

adults.69 Studies of DGL for peptic ulcers employed

dosages ranging from 760-2,280 mg DGL daily.

References

1. Olukoga A, Donaldson D. Historical perspectives

on health. The history of liquorice: the plant, its

extract, cultivation, and commercialisation and

etymology. J R Soc Health 1998;118:300-304.

2. Obolentseva GV, Litvinenko VI, Ammosov AS,

et al. Pharmacological and therapeutic properties

of licorice preparations (a review). Pharm Chem J

1999;33:24-31.

3. Yamamura Y, Kawakami J, Santa T, et al.

Pharmacokinetic profile of glycerrhizin in

healthy volunteers by a new high-performance

liquid chromatographic method. J Pharm Sci

1992;81:1042-1046.

4. Vaya J, Belinky PA, Aviram M. Antioxidant

constituents from licorice roots: isolation, structure

elucidation and antioxidative capacity toward LDL

oxidation. Free Radic Biol Med 1997;23:302-313.

5. Tamir S, Eizenberg M, Somjen D, et al. Estrogenlike

activity of glabrene and other constituents

isolated from licorice root. J Steroid Biochem Mol

Biol 2001;78:291-298.

6. Hattori M, Sakamoto T, Yamagishi T, et al.

Metabolism of glycyrrhizin by human intestinal

flora. II. Isolation and characterization of human

intestinal bacteria capable of metabolizing

glycyrrhizin and related compounds. Chem Pharm

Bull (Tokyo) 1985;33:210-217.

7. Akao T, Akao T, Hattori M, et al. Hydrolysis

of glycyrrhizin to 18 beta-glycyrrhetyl

monoglucuronide by lysosomal beta-Dglucuronidase

of animal livers. Biochem Pharmacol

1991;41:1025-1029.

8. Ploeger B, Mensinga T, Sips A, et al. The

pharmacokinetics of glycyrrhizic acid evaluated by

physiologically based pharmacokinetic modeling.

Drug Metab Rev 2001;33:125-147.

9. Crance JM, Biziagos E, Passagot J, et al. Inhibition

of hepatitis A virus replication in vitro by antiviral

compounds. J Med Virol 1990;31:155-160.

10. Van Rossum TG, Vulto AG, Hop WC, et al.

Intravenous glycyrrhizin for the treatment of

chronic hepatitis C: a double-blind, randomized,

placebo-controlled phase I/II trial. J Gastroenterol

Hepatol 1999;14:1093-1099.

11. Su XS, Chen HM, Wang LH, et al. Clinical and

laboratory observation on the effect of glycyrrhizin

in acute and chronic viral hepatitis. J Tradit Chin

Med 1984;4:127-132.

12. Baba M, Shigeta S. Antiviral activity of

glycyrrhizin against Varicella-zoster virus in vitro.

Antiviral Res 1987;7:99-107.

13. Hattori T, Ikematsu S, Koito A, et al. Preliminary

evidence for inhibitory effect of glycyrrhizin on

HIV replication in patients with AIDS. Antiviral

Res 1989;11:255-261.

14. Ito M, Sato A, Hirabayashi K, et al. Mechanism of

inhibitory effect of glycyrrhizin on replication of

human immunodeficiency virus (HIV). Antiviral

Res 1988;10:289-298.

15. Pompei R, Flore O, Marccialis MA, et al.

Glycyrrhizic acid inhibits virus growth and

inactivates virus particles. Nature 1979;281:689-

690.

16. Partridge M, Poswillo DE. Topical carbenoxolone

sodium in the management of herpes simplex

infection. Br J Oral Maxillofac Surg 1984;22:138-

145.

17. Numazaki K, Umetsu M, Chiba S. Effect of

glycyrrhizin in children with liver dysfunction

associated with cytomegalovirus infection. Tohoku

J Exp Med 1994;172:147-153.

18. Armanini D, Karbowiak I, Funder JW. Affinity

of liquorice derivatives for mineralocorticoid and

glucocorticoid receptors. Clin Endocrinol (Oxf)

1983;19:609-612.

Glycyrrhiza glabra Monograph

Page 236 Alternative Medicine Review u Volume 10, Number 3 u 2005

19. Okimasu E, Moromizato Y, Watanabe S, et al.

Inhibition of phospholipase A2 and platelet

aggregation by glycyrrhizin, an antiinflammation

drug. Acta Med Okayama 1983;37:385-391.

20. Ohuchi K, Tsurufuji A. A study of the antiinflammatory

mechanism of glycyrrhizin. Mino

Med Rev 1982;27:188-193.

21. Akamatsu H, Komura J, Asada Y, Niwa Y.

Mechanism of anti-inflammatory action of

glycyrrhizin: effect on neutrophil functions

including reactive oxygen species generation.

Planta Med 1991;57:119-121.

22. Wang ZY, Nixon DW. Licorice and cancer. Nutr

Cancer 2001;39:1-11.

23. Haraguchi H, Yoshida N, Ishikawa H, et al.

Protection of mitochondrial functions against

oxidative stresses by isoflavans from Glycyrrhiza

glabra. J Pharm Pharmacol 2000;52:219-223.

24. Nagai T, Egashira T, Yamanaka Y, Kohno M. The

protective effect of glycyrrhizin against injury of

the liver caused by ischemia-reperfusion. Arch

Environ Contam Toxicol 1991;20:432-436.

25. Van Rossum TG, Vulto AG, Hop WC, Schalm

SW. Glycyrrhizin-induced reduction of ALT in

European patients with chronic hepatitis C. Am J

Gastroenterol 2001;96:2432-2437.

26. Tamir S, Eizenberg M, Somjen D, et al. Estrogenic

and antiproliferative properties of glabridin from

licorice in human breast cancer cells. Cancer Res

2000;60:5704-5709.

27. Shiota G, Harada K, Ishida M, et al. Inhibition

of hepatocellular carcinoma by glycyrrhizin in

diethylnitrosamine-treated mice. Carcinogenesis

1999;20:59-63.

28. Nishino H, Kitagawa K, Iwashima A. Antitumorpromoting

activity of glycyrrhetic acid in mouse

skin tumor formation induced by 7,12 dimethylbenz[

a]anthracene plus teleocidin. Carcinogenesis

1984;5:1529-1530.

29. Liu W, Kato M, Akhand A, et al. The herbal

medicine Sho-saiko-to inhibits the growth of

malignant melanoma cells by up-regulating Fasmediated

apoptosis and arresting cell cycle through

down regulation of cyclin dependent kinases. Int J

Oncol 1998;12:1321-1326.

30. Van Marle J, Aarsen PN, Lind A, et al.

Deglycyrrhizinised liquorice (DGL) and the

renewal of rat stomach epithelium. Eur J

Pharmacol 1981;72:219-225.

31. Goso Y, Ogata Y, Ishihara K, Hotta K. Effects

of traditional herbal medicine on gastric mucin

against ethanol-induced gastric injury in rats. Comp

Biochem Physiol C Pharmacol Toxicol Endocrinol

1996;113:17-21.

32. Tsubota A, Kumada H, Arase Y, et al. Combined

ursodeoxycholic acid and glycyrrhizin therapy for

chronic hepatitis C virus infection: a randomized

controlled trial in 170 patients. Eur J Gastroenterol

Hepatol 1999;11:1077-1083.

33. Iino S, Tango T, Matsushima T, et al. Therapeutic

effects of stronger neo-minophagen C at different

doses on chronic hepatitis and liver cirrhosis.

Hepatol Res 2001;19:31-40.

34. Da Nagao Y, Sata M, Suzuki H, et al. Effectiveness

of glycyrrhizin for oral lichen planus in patients

with chronic HCV infection. J Gastroenterol

1996;31:691-695.

35. Hirabayashi K, Iwata S, Matsumoto H, et al.

Antiviral activities of glycyrrhizin and its modified

compounds against human immunodeficiency

virus type 1 (HIV-1) and Herpes simplex virus

type 1 (HSV-1) in vitro. Chem Pharm Bull (Tokyo)

1991;39:112-115.

36. Pompei R, Pani A, Flore O, et al. Antiviral activity

of glycyrrhizic acid. Experientia 1980;36:304.

37. Aikawa Y, Yoshiike T, Ogawa H. Effect of

glycyrrhizin on pain and HLA-DR antigen

expression on CD8-positive cells in peripheral

blood of herpes zoster patients in comparison with

other antiviral agents. Skin Pharmacol 1990;3:268-

271.

38. Numazaki K, Chiba S. Natural course and trial

of treatment for infantile liver dysfunction

associated with cytomegalovirus infections. In Vivo

1993;7:477-480.

39. Numazaki K. Glycyrrhizin therapy for liver

dysfunction associated with cytomegalovirus

infection in immunocompetent children.

Antimicrobics Infect Dis Newsl 1998;17:70-71.

40. Arase Y, Ikeda K, Murashima N, et al. The long

term efficacy of glycyrrhizin in chronic hepatitis C

patients. Cancer 1997;79:1494-1500.

41. Kumada H. Long-term treatment of chronic

hepatitis C with glycyrrhizin [Stronger Neo-

Minophagen C (SNMC)] for preventing liver

cirrhosis and hepatocellular carcinoma. Oncology

2002;62:94-100.

42. Poswillo D, Partridge M. Management of recurrent

aphthous ulcers. Br Dent J 1984;157:55-57.

43. Das SK, Das V, Gulati AK, Singh VP.

Deglycyrrhizinated liquorice in apthous ulcers. J

Assoc Physicians India 1989;37:647.

44. Loginov AS, Speransky MD, Speranskaya IE,

et al. The effectiveness of carbenoxolone in the

treatment of gastro-duodenal ulcer patients. Scand J

Gastroenterol Suppl 1980;65:85-91.

45. Shibata S. A drug over the millennia:

pharmacognosy, chemistry, and pharmacology of

licorice. Yakugaku Zasshi 2000;120:849-862.

Monograph Glycyrrhiza glabra

Alternative Medicine Review u Volume 10, Number 3 u 2005 Page 237

46. Morgan AG, McAdam WA, Pacsoo C,

Darnborough A. Comparison between cimetidine

and Caved-S in the treatment of gastric ulceration,

and subsequent maintenance therapy. Gut

1982;23:545-551.

47. Morgan AG, Pacsoo C, McAdam WA. Maintenance

therapy: a two year comparison between Caved-

S and cimetidine treatment in the prevention

of symptomatic gastric ulcer recurrence. Gut

1985;26:599-602.

48. Turpie AG, Runcie J, Thomson TJ. Clinical trial of

deglycyrrhizinized liquorice in gastric ulcer. Gut

1969;10:299-302.

49. Glick L. Deglycyrrhizinated liquorice for peptic

ulcer. Lancet 1982;2:817.

50. Peterson WL. Helicobacter pylori and peptic ulcer

disease. N Engl J Med 1991;324:1043-1048.

51. Parsonnet J. Helicobacter pylori in the stomach – a

paradox unmasked. N Engl J Med 1996;335:278-

280.

52. Fukai T, Marumo A, Kaitou K, et al. Anti-

Helicobacter pylori flavonoids from licorice

extract. Life Sci 2002;71:1449-1463.

53. Tewari SN, Wilson AK. Deglycyrrhizinated

liquorice in duodenal ulcer. Practitioner

1973;210:820-823.

54. Kassir ZA. Endoscopic controlled trial of four

drug regimens in the treatment of chronic duodenal

ulceration. Ir Med J 1985;78:153-156.

55. Armanini D, De Palo CB, Mattarello MJ, et al.

Effect of licorice on the reduction of body fat

mass in healthy subjects. J Endocrinol Invest

2003;26:646-650.

56. Armanini D, Mattarello MJ, Fiore C, et al. Licorice

reduces serum testosterone in healthy women.

Steroids 2004;69:763-766.

57. Evans FQ. The rational use of glycyrrhetinic acid in

dermatology. Br J Clin Pract 1958;12:269-274.

58. Amer M, Metwalli M. Topical liquiritin improves

melasma. Int J Dermatol 2000;39:299-301.

59. Takeda H, Ohta K, Niki H, et al. Eosinophilic

peritonitis responding to treatment with

glycyrrhizin. Tokai J Exp Clin Med 1991;16:183-

186.

60. Basso A, Dalla Paola L, Erle G, et al. Licorice

ameliorates postural hypotension caused by

diabetic autonomic neuropathy. Diabetes Care

1994;17:1356.

61. Kolarski V, Petrova-Shopova K, Vasileva E, et al.

Erosive gastritis and gastroduodenitis – clinical,

diagnostic and therapeutic studies. Vutr Boles

1987;26:56-59. [Article in Bulgarian]

62. Chen M, Theander TG, Christensen SB, et al.

Licochalcone A, a new anti-malarial agent, inhibits

in vitro growth of the human malaria parasite

Plasmodium falciparum and protects mice from

P. yoelii infection. Antimicrob Agents Chemother

1994;38:1470-1475.

63. Christensen SB, Ming C, Anderson L, et al. An

antileishmanial chalcone from Chinese licorice

roots. Planta Med 1994;60:121-123.

64. Parle M, Dhingra D, Kulkarni SK. Memorystrengthening

activity of Glycyrrhiza glabra in

exteroceptive and interoceptive behavioral models.

J Med Food 2004;7:462-466.

65. Hoes AW, Grobbee DE, Peet TM, Lubsen J. Do

non-potassium-sparing diuretics increase the risk

of sudden cardiac death in hypertensive patients?

Recent evidence. Drugs 1994;47:711-733.

66. Clyburn EB, DiPette DJ. Hypertension induced

by drugs and other substances. Semin Nephrol

1995;15:72-86.

67. Olukoga A, Donaldson D. Liquorice and its health

implications. J R Soc Health 2000;120:83-89.

68. Stormer FC, Reistad R, Alexander J. Glycyrrhizic

acid in liquorice – evaluation of health hazard.

Food Chem Toxicol 1993;31:303-312.

69. Walker BR, Edwards CR. Licorice-induced

hypertension and syndromes of apparent

mineralocorticoid excess. Endocrinol Metab Clin

North Am 1994;23:359-377.

Monday, January 2, 2012

Practice regulation for Siddha doctors

Practitioners of Indian Medicine
( Standards of Professional Conduct, Etiquette and Code of Ethics )
Regulations, 1982

G.S.R.-In exercise of the powers conferred by clause (1) of section 36 read with sub section (1) and (2) of section 26 of the Indian Medicine, Central Council Act 1970 (48 of 1970), the Central Council of Indian Medicine, with the previous sanction of the Central Government, hereby makes the following regulations for laying down standards of professional conduct, etiquette and code of ethics to be observed by practitioners of Indian, Medicine namely :-

PART I

PRELIMINARY

1.Short title and commencement.-

(1) These regulations may be called the Practitioners of Indian Medicine (Standards of Professional Conduct, Etiquette and Code of Ethics) Regulations, 1982.

(2) They shall come into force on the date of their publication in the Official Gazette.

2. Definitions.-

(1) In these regulations, unless the context otherwise requires :-
(a) "Act" means the Indian Medicine Central Council Act, 1970 (48 of 1970);
(b) "Form" means a form appended to these rules;
(c) "Practitioner of Indian medicine" means the Physicians and Surgeons of Indian Medicine who are for the time being enrolled on any State Register of Indian Medicine and who possess any of the recognised medical qualifications;
(d) "Section" means section of the Act.
(2) Words and expressions used but not defined in; these regulations shall have the meanings assigned to them in the Act.

3. Declaration.-
Every practitioner of Indian Medicine shall, within a period of 30 days from the date of commencement of these regulations, and every practitioner of Indian medicine who gets himself registered after the commencement of these regulations shall, within a period of 30 days from such registration, make before the Registrar of the State Council or the Board, a declaration in Form A and shall agree to abide by the same.

PART II
PROFESSIONAL CONDUCT AND ETIQUETTE DUTIES AND OBLIGATIONS OP PRACTITIONERS OF INDIAN MEDICINE TOWARDS PATIENTS AND PUBLIC

4. Character of the Practitioners of Indian Medicine-

The main object of the medical profession is to render service to humanity. Whosoever chooses this profession, assumes the obligation to conduct himself in accordance with its ideals. A practitioner of Indian medicine shall be an upright man, instructed in the art and science of healing. He shall keep himself pure in character and be diligent in caring for the sick. He shall be modest, sober, patient, prompt to do his duty without anxiety and, pious in all the actions of his life.

5.Duties of practitioners of Indian medicine towards their patients.-

(1) A practitioner of Indian medicine shall be ready to respond to the calls of the patients in emergencies for the sake of humanity and the noble traditions of the profession, though he is not bound, to treat each and every one asking his services.
(2) He shall not permit, considerations of religion, nationality, race, caste, creed, party politics or social standing to intervene in his duties towards patients.

6. Practitioner's responsibility.- A practitioner of Indian medicine shall merit the confidence of patients entrusted to his care, rendering to each a full measure of service and devotion and shall try continuously to improve his knowledge and skill. He shall make available to his patients and colleagues the benefits of his professional attainment. The honoured ideals of the medical profession imply that the responsibility of such practitioner shall extend not only to individuals but also to society.

7. Patience, delicacy and secrecy.-Patience and delicacy shall characterise the practitioner of Indian medicine. Confidence concerning individuals or domestic life entrusted by patients to a practitioner of Indian medicine and defects in the disposition or character of patients observed during medical attendance shall never be revealed unless their revelation is required by law. Sometimes, however, a practitioner must determine whether his duties to society require him to employ knowledge obtained through confidences to him as such practitioner to protect a healthy person against a communicable disease to which he is about to be exposed. In such instances, the practitioners of Indian medicine shall act as he would desire another to act towards one of his own family in like circumstances.

8. Prognosis.- A practitioner of Indian medicine shall neither exaggerate nor minimise the gravity of a patient's condition and shall assure himself that the patients, his relatives or his responsible friends have such knowledge of the patient's condition as will serve the best interests of the patient and the family.

9. The patient must not be neglected.--A practitioner of Indian medicine shall be free to choose whom he will serve. He shall, however, respond to any request for his assistance in any emergency or whenever temperate public opinion expect his services. Once having undertaken a case, the practitioner of Indian Medicine shall not neglect the patient, nor shall he withdraw from the case without giving notice to the patient, his relatives or his responsible friends sufficiently in advance to allow them to secure another medical attendant. No provisionally or fully registered medical practitioner of Indian medicine shall wilfully commit an act of negligence that may deprive his patient or patients from necessary medical care.

10. Upholding the honour of the profession.- A practitioner of Indian medicine shall uphold the dignity and honour of his profession.

11. Engagement for an obstetric case.-If a practitioner of Indian medicine agrees to attend a women during her confinement, he must do so. Inability to do so on an excuse of any other engagement is not tenable except when he is already engaged on a similar or other serious case. When a practitioner, who has been engaged to attend an obstetric case, is absent and another is sent for and delivery accomplished, the acting practitioner is entitled to his professional fees, but shall secure the patient's consent to resign on the arrival of the practitioner engaged earlier.

12. Practitioner as a Citizen.-A practitioner of Indian medicine as a good citizen, possessed of special training, shall advise concerning the health of the community wherein he dwells. He shall lend his support in enforcing the laws of the community and in sustaining in the institutions that advance the interests of humanity. He shall cooperate with the proper authorities in the administration of sanitary laws and regulations.

13. Public Health.-A practitioner of Indian medicine especially engaged in public health work, shall enlighten the public concerning measures for the prevention of epidemics and communicable diseases. At all times, the practitioner shall notify the constituted public health authorities of every case of communicable disease under his care, in accordance with the laws, rules and regulations of the health authorities. When an epidemic prevails, he shall continue his labour without regard to the risk of his own health.

PART III

DUTY OF ONE PRACTITIONER TOWARDS ANOTHER PRACTITIONER
14. Dependence of practitioners on each other,- There is no rule that a practitioner of Indian medicine shall not charge another practitioner for his services, but a practitioner shall cheerfully and without recompense give his professional services to another practitioner or his dependents if they are in the vicinity.

15. Compensation for expenses.-A practitioner of Indian medicine shall consider it a privilege to render gratutious service to all practitioners and their immediate family dependents. When he is called from a distance to attend or advise another practitioner or his dependents, reimbursement shall be made to him for travelling and other incidental expenses.

16. Consultation to be encouraged.-In case of serious illness, especially in doubtful or difficult conditions, a practitioner may request consultation.

17. Consultation for patients benefit.-In every consultation, the benefit to the patient is of first importance. All practitioners interested in the case shall be candid with the patient, a member of his family or responsible friend.

18. Punctuality in consultation.-Utmost punctuality shall be observed by a practitioner of Indian medicine in meeting for consultation.

19. Conduct in consultation.-In consultations, no insincerity, rivalry or envy shall be indulged in. All due respect shall be observed towards the practitioners incharge of the case, and no statement or remark be made, which would impair the confidence reposed in him. For this purpose, no discussion shall be carried on in the presence of the patient or his representatives.

20. Statement to patient after consultation.- (1) All statements of the case to the patient or his representatives shall take place in the presence of all the practitioners consulting, except as otherwise agreed the announcement of the opinion to the patient or his relatives or friends shall rest with the practitioner initially attending on the patient.

(2) Difference of opinion shall not be divulged unnecessarily but when there is an irreconciliable difference of opinion the circumstances shall be frankly and impartially explained to the patient or his relatives or friends. It would be open to them to seek further advice, if they so desire.

21. Treatment after cosultation.-No decision shall restrain the attending practitioner of Indian medicine from making such subsequent variations in the treatment as any unexpected changes may require, but at the next consultation, reasons for the variations shall be stated. The same privilege, with its obligations belongs to the consultant when sent for in an emergency during the absence of attending practitioner of Indian medicine. The attending practitioner may prescribe at any time for the patient, the consultant only in case of emergency.

22. Visiting another practitioner's cases.-A practitioner of Indian medicine called to visit a patient who has recently been under the care of another practitioner in the same illness, shall not take charge of, nor prescribe for such patient, except in a case of emergency when he shall communicate to the former explaining the circumstances under which the patient was seen and treatment given, or when the practitioner has relinquished his case, or when the patient has notified such practitioner to discontinue his services or unless the patient specifically refuses to go back to his original practitioner. When it becomes the duty of practitioner occupying an official position to see and report upon an illness or injury, he shall communicate to the practitioner attending so as to give him an option for being present. Such practitioner shall avoid remarks upon the diagnosis or the treatment that has been adopted.

23. Patient referred to specialists.-When a patient is referred to a specialist by the attending practitioner, a statement of the case shall be given to the specialist who shall communicate his opinion in writing in a closed cover direct to the attending practitioner.

PART IV

CODE OF ETHICS

24. Advertising.-Solicitation of patients directly or indirectly either personally or by advertisement in the newspaper,by placards or by distribution of circular cards or hand bills by a practitioner of Indian medicine is unethical. A practitioner Shall not make use of or aid or permit others to make use of him or his name and/or photograph as subject of any form or manner of advertising or publicity. This provision shall not apply to authors of purely medical literature written for the advancement of the profession and science.

25. Nomenclature of qualification.-It shall be compulsory for a practitioner of Indian medicine to affix the correct degree or diploma before or after his name.

26. Change of address and announcement relating thereto-A notice of change of address shall be intimated by every practitioner of Indian medicine to the concerned State Board or Council and the Control Council.

A practitioner may issue a formal announcement in the Press one-insertion in one or more papers, regarding the following :-

(a) On starting practice;
(b) On change of type of practice;
(c) On change of address;
(d) On temporary absence from duty;
(e) On resumption of practice;
(f) On succeeding to another practice.

27. Payment for professional services.-A practitioner of Indian medicine shall not enter into a contract of "No cure, no payment".

28. Rebates and commission.-A practitioner of Indian medicine shall not give, solicit, or receive nor shall he offer to give, solicit or receive, any gift, gratuity, commission or bonus in consideration of or in return for the referring, recommending or procuring of any patient for medical, surgical or other treatment. He shall not directly or by any subterfuge participate in or be a party to the act of division, transference, assignment, subordination, rebating, splitting or refunding of any fee for medical, surgical or other treatment.

29. Evasion of legal restriction.-A practitioner of Indian medicine shall observe the laws of the country in regulating the practice of medicine and shall not assist others to evade such laws.

30. Professional certificates, reports and other documents.- (1) A registered practitioner of Indian medicine is, in certain cases, bound by law to give or may be called upon or requested from time to time to give certificate, notifications, reports or similar documents signed by him in his professional capacity for subsequent use in the course of justice or for administrative purposes. (2) Such documents include among other certificate, or reports:- (a) under the Acts relating to birth, death or disposal of the dead; (b) under the Acts relating to Lunacy and mental deficiency and the rules made thereunder; (c) under the vaccination Acts and the regulations made thereunder; (d) under the Factory Acts and the regulations made thereunder; (e) under the Education Acts; (f) under the Public Health Acts and the orders made thereunder; (g) under the Workmen's Compensation, Act; (h) under the Acts and order relating to the notification of infectious diseases; (i) under the Employee's State Insurance Act; (j) in connection with sick benefit insurance and friendly societies; (k) under the Merchant Shipping Act; (l) for procuring the issuing of passports; (m) for excusing attendance in courts of justice, in public services, in public offices or in ordinary employments; (n) in connection with rural and military matters; (o) in connection with matters under the control of ministry of the pensions. (3) Any practitioner of Indian medicine who shall be shown to have signed or given under his name and authority any such certificate, notification, report or similar document which is untrue, misleading or improper is liable for professional misconduct or disciplinary action under the Act or under any law for the time being in force in any State regulating the registration of such practitioner, to have his name removed from the Central Register of Indian Medicine and the provisions of section 27 shall apply.

31. Register of medical certificate issued by practitioner.-A practitioner of Indian medicine shall maintain a register of medical certificates giving full details of the certificates issued. When issuing a medical certificate, he shall always enter the identification marks of the patient and keep a copy of the certificate. He shall not omit to obtain the signature or thumb mark, address and identification marks of the patient on the medical certificates and on the copies kept by him.

PART V

DISCIPLINARY ACTION

32. (1) The Central Council desires to bring the notice of the practitioners of Indian Medicine the following list of offences which constitute professional misconduct and may warrant disciplinary action against them under the Act or under any law for the time being in force in any State regulating the registration of such practitioners.

LIST

(i) Adultry or improper conduct or association with a patient. Any practitioner of Indian medicine who abuses his professional position by committing any adultry or improper conduct with a patient or by maintaining an improper association with a patient, is liable for disciplinary action under the Act or under any law for the time being in force in any State regulating the registration of such practitioners;

(ii) any offices involving moral turpitude.

(iii) if convicted under the provisions of the Drugs and Cosmetic Act, 1940 or the rules made hereunder.

(iv) if convicted for selling Scheduled poison to the Public under the cover of his own qualification except to his patient, and in accordance with the provision of any law for time being in force,

(v) performing on enabling unqualified person to perform an abortion or any illegal operation for which there is no medical, surgical or psychological indication;

(vi) A practitioner of Indian medicine shall not issue certificates of efficiency in Indian Medicine to unqualified or non-medical person.

(Note : The foregoing does not apply so as to restrict the proper training and instruction of bonafide students, legitimate employees or practitioners, midwives, dispensers, surgical attendants, or skilled mechanical and technical assistants under the personal supervision of practitioners).

(vii) It is improper for a practitioner of Indian medicine to use an unusually large sign board and write on it anything other than his name, qualifications obtained from a University or astatutory body, titles and name of his speciality. The same should be comens on his prescription papers. It is improper to affix a sign-board on a chemist's shop or in places where he does not reside or work.

(viii) Do not disclose the secrets of a patient that have been learnt in the exercise of the profession. Those may be disclosed only in a Court of Law under orders of the Presiding Judge.

(ix) Refusing on religious grounds alone to give assistance in conduct of sterility, birth control, craniotomies on living children, and therapeutic abortions when there is medical indication; unless the practitioner of Indian medicine feels himself incompetent to do so.

(x) Before performing an operation the consent in writing shall be obtained; from, the husband or wife, parent or guardian in the case of a minor, or the patient himself as the case may be. In an operation which may result in sterility the consent of both husband and wife is needed.

(xi) The photographs or case reports of patients shall not be published in any medical or other journal in a manner by which their identity could be made out without their permission. Should the identity be not disclosed his consent is not needed.

(xii) If a practitioner of Indian, medicine is running a Nursing home and he employs assistants to help him the ultimate responsibility rests on such practitioner.

(xiii) No practitioner of Indian medicine shall exhibit publically the scale of fees. But there is no objection to the same being put in the practitioners' consulting or waiting room.

(xiv) No practitioner of Indian medicine shall use touts or agents for procuring patients.

(xv) Advertisement through hoarding and tour programmes shall be unethical.

(2) The appropriate authority that is to say, the State Board or the State Council may issue a letter of warning or may direct the removal altogether or for specified period from the register the name of any practitioner of Indian medicine who has been convicted of any specified offence or who after an inquiry, at which opportunity has been given to him to. be heard in, person or through a lawyer, has been held guilty of professional mis-conduct or infamous conduct in any professional respect, and the provisions of section 27 shall apply